Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.
Enzo Biochem Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.78|
|52 Week High||US$1.80|
|52 Week Low||US$4.85|
|1 Month Change||8.93%|
|3 Month Change||23.93%|
|1 Year Change||75.81%|
|3 Year Change||15.24%|
|5 Year Change||-36.26%|
|Change since IPO||37.26%|
Recent News & Updates
Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|ENZ||US Healthcare||US Market|
Return vs Industry: ENZ exceeded the US Healthcare industry which returned 23.5% over the past year.
Return vs Market: ENZ exceeded the US Market which returned 27.6% over the past year.
Stable Share Price: ENZ is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ENZ's weekly volatility (6%) has been stable over the past year.
About the Company
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers.
Enzo Biochem Fundamentals Summary
|ENZ fundamental statistics|
Is ENZ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ENZ income statement (TTM)|
|Cost of Revenue||US$60.83m|
Last Reported Earnings
Apr 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.026|
|Net Profit Margin||1.14%|
How did ENZ perform over the long term?See historical performance and comparison
Is Enzo Biochem undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ENZ's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ENZ's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ENZ is poor value based on its PE Ratio (143x) compared to the US Healthcare industry average (21.1x).
PE vs Market: ENZ is poor value based on its PE Ratio (143x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ENZ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ENZ is good value based on its PB Ratio (2.8x) compared to the US Healthcare industry average (2.9x).
How is Enzo Biochem forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enzo Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Enzo Biochem performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ENZ has a high level of non-cash earnings.
Growing Profit Margin: ENZ became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ENZ's earnings have declined by 64% per year over the past 5 years.
Accelerating Growth: ENZ has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ENZ has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (32.2%).
Return on Equity
High ROE: ENZ's Return on Equity (2%) is considered low.
How is Enzo Biochem's financial position?
Financial Position Analysis
Short Term Liabilities: ENZ's short term assets ($71.3M) exceed its short term liabilities ($29.2M).
Long Term Liabilities: ENZ's short term assets ($71.3M) exceed its long term liabilities ($19.4M).
Debt to Equity History and Analysis
Debt Level: ENZ's debt to equity ratio (17.8%) is considered satisfactory.
Reducing Debt: ENZ's debt to equity ratio has increased from 4.5% to 17.8% over the past 5 years.
Debt Coverage: ENZ's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ENZ's interest payments on its debt are well covered by EBIT.
What is Enzo Biochem current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ENZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ENZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ENZ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ENZ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ENZ's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Elazar Rabbani (78 yo)
Dr. Elazar Rabbani, Ph.D. has been a Director of Enzo Clinical Labs, Inc., and Enzo Biochem Inc., since 1976. He Co-Founded Enzo Biochem Inc. in 1976 and has been its Chief Executive Officer and Chairman o...
CEO Compensation Analysis
Compensation vs Market: Elazar's total compensation ($USD1.49M) is above average for companies of similar size in the US market ($USD1.08M).
Compensation vs Earnings: Elazar's compensation has been consistent with company performance over the past year.
Experienced Management: ENZ's management team is seasoned and experienced (12.8 years average tenure).
Experienced Board: ENZ's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ENZ insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Enzo Biochem, Inc.'s employee growth, exchange listings and data sources
- Name: Enzo Biochem, Inc.
- Ticker: ENZ
- Exchange: NYSE
- Founded: 1976
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$183.223m
- Shares outstanding: 48.47m
- Website: https://www.enzo.com
Number of Employees
- Enzo Biochem, Inc.
- 527 Madison Avenue
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 22:12|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.